5 analysts have expressed a variety of opinions on Fate Therapeutics FATE over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 1 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have recently evaluated Fate Therapeutics and provided 12-month price targets. The average target is $7.6, accompanied by a high estimate of $10.00 and a low estimate of $7.00. This current average reflects an increase of 68.89% from the previous average price target of $4.50.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light on the perception of Fate Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Raghuram Selvaraju | HC Wainwright & Co. | Maintains | Neutral | $7.00 | - |
| Michael Ulz | Morgan Stanley | Raises | Equal-Weight | $7.00 | $3.00 |
| Etzer Darout | BMO Capital | Raises | Market Perform | $7.00 | $6.00 |
| Peter Lawson | Barclays | Raises | Overweight | $10.00 | $6.00 |
| David Nierengarten | Wedbush | Raises | Neutral | $7.00 | $3.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Fate Therapeutics compared to the broader market.
- Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Fate Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Fate Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
All You Need to Know About Fate Therapeutics
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Financial Milestones: Fate Therapeutics's Journey
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Fate Therapeutics's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -96.22% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Fate Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -2632.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Fate Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -11.44%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.4%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 0.28, Fate Therapeutics faces challenges in effectively managing its debt levels, indicating potential financial strain.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
